<DOC>
	<DOCNO>NCT01687998</DOCNO>
	<brief_summary>The purpose ACCELERATE study evaluate efficacy safety evacetrapib participant high-risk vascular disease ( HRVD ) .</brief_summary>
	<brief_title>A Study Evacetrapib High-Risk Vascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Diagnosis high risk vascular disease ( HRVD ) ( , meet least one disease diagnostic criterion : 1 ) History acute coronary syndrome ( ACS ) ( , ≥30 day 365 day discharge ACS ) 2 ) cerebrovascular atherosclerotic disease 3 ) peripheral arterial disease 4 ) diabetes mellitus document coronary artery disease clinically stable ( judge responsible physician ) . Must treat statin least 30 day prior screen . If treat statin must document statin intolerance , contraindication statin Have screen highdensity lipoprotein cholesterol ( HDLC ) ≤80 milligram per deciliter ( mg/dL ) ( ≤2.1 millimole per liter [ mmol/L ] ) Have screen triglyceride ( TG ) ≤400 mg/dL ( ≤4.5 mmol/L ) Meet 1 follow criterion : screening lowdensity lipoprotein cholesterol ( LDLC ) 10 mg/dL ( 0.3 mmol/L ) target choose investigator ( either LDLC &lt; 100 mg/dL [ &lt; 2.6 mmol/L ] LDLC &lt; 70 mg/dL [ &lt; 1.8 mmol/L ] ) , OR LDLC great target , participant must maximum tolerated statin dose ( least 30 day ) , document statin intolerance , contraindication statin Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Have previously complete withdrawn study , withdrawn study investigate evacetrapib Female participant know pregnant breastfeed Women childbearing potential , test positive pregnancy screen randomization , agree use reliable method birth control study History transient ischemic attack ( TIA ) ischemic stroke &lt; 30 day ACS &lt; 30 day Any read systolic blood pressure ≥180 millimeter mercury ( mm Hg ) diastolic blood pressure ≥110 mm Hg screen randomization History hemorrhagic stroke intracranial hemorrhage New York Heart Association class III IV congestive heart failure Serum creatinine &gt; 2.2 mg/dL ( &gt; 194.5 micromole per liter [ μmol/L ] ) screen Clinically active liver disease . Participants exclude due Gilbert 's Syndrome history cholelithiasis/cholecystectomy History malignancy within precede 3 year prior screen Known malabsorption syndrome exception lactose intolerance Participants know history primary secondary hyperaldosteronism Participants history intolerance/hypersensitivity cholesterol ester transfer protein ( CETP ) inhibitors Any clinically significant medical condition accord investigator could interfere participation study Participants whose life expectancy anticipate less 4 year Unable unwilling comply study requirement , deem investigator unfit study Have history drug , alcohol , substance abuse within past 6 month , assess investigator Concurrent anticipate need treatment niacin &gt; 250 mg/day chronic administration drug exclusion list Previous exposure CETP inhibitor dalcetrapib evacetrapib within last 3 month anacetrapib within last 12 month Any plan coronary angiography coronary revascularization procedure . If angiography revascularization plan , participant may screen enrol planned procedure complete .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>